Research, Funding and Drug Development

Improvements in outcomes for cancer patients require continued research and innovation.  ACS CAN advocates for robust federal funding for cancer research, as well as research and drug approval policies that accelerate the development of new treatments while still ensuring patient safety.

Research, Funding and Drug Development Resources:

In response to the Biden Administration's request for information regarding actions being taken toward the achievement the Cancer Moonshot goals, ACS and ACS CAN submitted a list of major initiatives and activites the organizations are pursuing. 

The Office of Congressionally Directed Medical Research Programs (CDMRP) was established by the Department of Defense (DOD) and is currently a collection of 36 programs that target research funding to specific diseases including cancer. 

ACS CAN conducted a survey of 315 oncology providers examining common barriers providers face in performing recommended cancer biomarker testing.

 

ACS CAN and more than 150 organizations representing patients, providers and health equity advocates sent a letter to Congress urging them to pass the Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act into law to remove barriers to clinical trial enrollment.

The DIVERSE Trials Act (H.R. 5030/S. 2706) could increase racial, socioeconomic and geographic diversity in clinical trials and make it easier for all cancer patients to participate. 

President Joe Biden has called for the creation of an Advanced Research Projects Agency-Health

In response to a request for information related to the 21st Century Cures 2.0 initiative, ACS CAN provided comments regarding the creation of the Advanced Research Projects Agency for Health (ARPA-H). 

Disparities have been described in various domains of cancer research, each issue exists separately and has a different relationship to understanding and addressing disparities in clinical outcomes. The various domains of research disparities are explored in Cancer Research and Disparities: Understanding and Addressing the Issues. 

ACS CAN submitted comments to the National Institute of Health Request for Information: Inviting Comments and Suggestions to Advance and Strengthen Racial Equity, Diversity, and Inclusion in the Biomedical Research Workforce and Advance Health Disparities and Health Equity Research